CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign
Why now
Thesis: Routine seasonal supply update
Catalyst to watch: Flu season severity or order volumes
Main risk: No pricing or volume disclosure
Why it matters
Flu vaccine supply expansion ahead of season; parent is ASX-listed, no guidance or volume figures given.
Details
HOLLY SPRINGS, N.C., Sept. 29, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign. With the majority of customer orders...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-29 13:30 UTC